International Medical Case Reports Journal (May 2021)
Dupilumab Induced Limbal Stem Cell Deficiency
Abstract
Urmi Mehta,1,2 Marjan Farid1 1Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, CA, 92697, USA; 2Western University of Health Sciences, Pomona, CA, 91766, USACorrespondence: Marjan FaridGavin Herbert Eye Institute, University of California, Irvine, CA, USATel +1 949 824-2020Email [email protected]: Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who developed limbal stem cell deficiency (LSCD) after prolonged Dupilumab use. A 56-year-old Caucasian male with a history of AD presented with gradual onset cloudy vision and extensive diffuse symblepharon resulting from Dupilumab treatment. He was diagnosed with cicatrizing blepharoconjunctivitis and secondary LSCD after slit lamp examination. In conclusion, LSCD secondary to cicatricial disease is a severe adverse ocular complication caused from long-term Dupilumab treatment.Keywords: limbal stem cell disease, symblepharon, cicatrizing blepharoconjunctivitis, Dupilumab, dupixent
